| About the authors |
|
vii | |
|
|
|
ix | |
| Acknowledgements |
|
xi | |
| Introduction |
|
xiii | |
|
What's in the monographs and how to use them |
|
|
1 | (12) |
|
5-Fluorouracil (5FU) continuous infusion (single-agent) |
|
|
13 | (4) |
|
ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) |
|
|
17 | (6) |
|
BCD (carmustine, cisplatin, dacarbazine; the `Dartmouth' regimen) |
|
|
23 | (4) |
|
BEP (3 day) and BEP (5 day) (bleomycin, etoposide, cisplatin) |
|
|
27 | (6) |
|
BIP (bleomycin, ifosfamide, cisplatin) |
|
|
33 | (6) |
|
BOP (bleomycin, vincristine, cisplatin) |
|
|
39 | (6) |
|
CAP (cyclophosphamide, doxorubicin, cisplatin) |
|
|
45 | (6) |
|
Capecitabine (single-agent) |
|
|
51 | (6) |
|
CAPOMEt (cyclophosphamide, doxorubicin, prednisolone, vincristine, methotrexate, etoposide) |
|
|
57 | (12) |
|
Carboplatin (single-agent) |
|
|
69 | (4) |
|
CAV (cyclophosphamide, doxorubicin, vincristine) |
|
|
73 | (4) |
|
Chlorambucil with or without prednisolone |
|
|
77 | (4) |
|
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) |
|
|
81 | (6) |
|
|
|
87 | (4) |
|
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) |
|
|
91 | (6) |
|
COP-X (cyclophosphamide, vincristine, prednisolone, liposomal daunorubicin) |
|
|
97 | (6) |
|
CT (carboplatin plus paclitaxel) |
|
|
103 | (4) |
|
C-VAMP (cyclophosphamide, vincristine, doxorubicin, methylprednisolone) |
|
|
107 | (6) |
|
de Gramont regimen and modified de Gramont (5-fluorouracil plus folinic acid) |
|
|
113 | (6) |
|
de Gramont regimen plus irinotecan (IrdG) and modified de Gramont plus irinotecan (IrMdG) (5-fluorouracil, folinic acid, irinotecan) |
|
|
119 | (6) |
|
de Gramont regimen plus oxaliplatin (OxdG) and modified de Gramont plus oxaliplatin (OxMdG) |
|
|
125 | (8) |
|
DHAP (dexamethasone, cytarabine, cisplatin) |
|
|
133 | (6) |
|
|
|
139 | (4) |
|
Doxorubicin (single-agent) |
|
|
143 | (4) |
|
DTIC (dacarbazine) (single-agent) |
|
|
147 | (4) |
|
ECF (epirubicin, cisplatin, 5-fluorouracil) |
|
|
151 | (6) |
|
EMI (IME, IMVP-16) (ifosfamide, methotrexate, etoposide) |
|
|
157 | (6) |
|
Epirubicin (single-agent) |
|
|
163 | (4) |
|
Etoposide (single-agent) oral |
|
|
167 | (4) |
|
FAC (CAF) (5-fluorouracil, doxorubicin, cyclophosphamide) |
|
|
171 | (4) |
|
FEC (5-fluorouracil, epirubicin, cyclophosphamide) |
|
|
175 | (4) |
|
Fludarabine IV (single-agent) |
|
|
179 | (4) |
|
Fludarabine oral (single-agent) |
|
|
183 | (4) |
|
FMD (fludarabine, mitoxantrone, dexamethasone) |
|
|
187 | (6) |
|
Gemcitabine (single-agent) |
|
|
193 | (4) |
|
Gemcitabine plus cisplatin |
|
|
197 | (6) |
|
Ifosfamide (single-agent) |
|
|
203 | (6) |
|
Irinotecan (CPT-11) (single-agent) |
|
|
209 | (4) |
|
Liposomal daunorubicin (single-agent) |
|
|
213 | (4) |
|
Liposomal doxorubicin (pegylated) (single-agent) |
|
|
217 | (8) |
|
Mayo regimen (folinic acid plus 5-fluorouracil) |
|
|
225 | (4) |
|
MCF (mitomycin, cisplatin, 5-fluorouracil) |
|
|
229 | (6) |
|
Melphalan (IV intermediate-dose) plus dexamethasone |
|
|
235 | (4) |
|
MIC (mitomycin, ifosfamide, cisplatin) |
|
|
239 | (6) |
|
MMM (mitomycin, methotrexate, mitoxantrone) |
|
|
245 | (4) |
|
MOPP (chlormethine, vincristine, prednisolone, procarbazine) |
|
|
249 | (6) |
|
MV (mitomycin, vinblastine) |
|
|
255 | (4) |
|
MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) |
|
|
259 | (6) |
|
MVP (mitomycin, vinblastine, cisplatin) |
|
|
265 | (4) |
|
NP (vinorelbine plus cisplatin) |
|
|
269 | (6) |
|
Paclitaxel (single-agent) |
|
|
275 | (4) |
|
Paclitaxel plus trastuzumab |
|
|
279 | (6) |
|
PCV (procarbazine, lomustine, vincristine) |
|
|
285 | (6) |
|
PE (cisplatin plus etoposide) |
|
|
291 | (4) |
|
PMB (cisplatin, methotrexate, bleomycin) |
|
|
295 | (6) |
|
PMitCEBO (prednisolone, mitoxantrone, cyclophosphamide, etoposide, bleomycin, vincristine) |
|
|
301 | (6) |
|
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) |
|
|
307 | (8) |
|
|
|
315 | (4) |
|
Temozolomide (single-agent) |
|
|
319 | (4) |
|
|
|
323 | (4) |
|
Trastuzumab (single-agent) |
|
|
327 | (4) |
|
VAD (vincristine, doxorubicin, dexamethasone) |
|
|
331 | (4) |
|
Vinorelbine (single-agent) |
|
|
335 | (4) |
|
VIP (etoposide, ifosfamide, cisplatin) |
|
|
339 | (6) |
|
XT (capecitabine plus docetaxel) |
|
|
345 | (8) |
|
Z-DEX (oral idarubicin plus dexamethasone) |
|
|
353 | (4) |
| Appendix 1 Dosage adjustment for cytotoxics in hepatic impairment |
|
357 | (18) |
| Appendix 2 Dosage adjustment for cytotoxics in renal impairment |
|
375 | (16) |
| Appendix 3 Example of a pharmacy patient record |
|
391 | (2) |
| Index |
|
393 | |
More info about Taylor & Francis e-books